Riskpilot← Back to searchSign inGet full accessLisubron AB
ABActiveOrg 5566545744Norrviksvägen 4Business and other management consultancy activities · NACE 7020Est. 20040 employees
Revenue 2024
SEK 0
EBITDA margin
—
-216% vs 2023
Equity ratio
74.4%
Financial strength
Net profit 2024
SEK -77K
-219% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -77K | -216% |
| Net profit | SEK -77K | -219% |
| Total assets | SEK 6,2M | +0% |
| Equity | SEK 4,6M | -9% |
| Employees | 0 | — |
Legal name
Lisubron AB
Org number
5566545744
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
24 januari 2004
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
FIRMAN TECKNAS VAR FÖR SIG AV LEDAMOTEN SUPPLEANTEN
Company purpose
Bolaget skall bedriva konsultverksamhet inom marknadsföring. Nystartad del av verksamheten skall bedriva verksamhet inom hälsokost och friskvård. Samt äga och förvalta fast egendom samt bedriva därmed förenlig verksamhet.
Address
Norrviksvägen 4
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | −0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −35 | −43 | −44 | −24 | −77 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | −35 | −43 | −44 | −24 | −77 |
| Net financials | — | — | 4 025 | 0 | 1 |
| Profit before tax | 15 | −43 | 3 981 | −24 | −77 |
| Tax | −0 | −0 | — | — | — |
| Net profit | 15 | −43 | 3 981 | −24 | −77 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 6 171 | 6 158 | 6 165 | 6 172 | 6 179 |
| Equity | 2 761 | 2 318 | 5 700 | 5 076 | 4 599 |
| Long-term debt | 2 995 | 0 | — | 1 081 | 1 466 |
| Short-term debt | 415 | 3 840 | 465 | 15 | 113 |
| Total debt | 3 410 | 3 840 | 465 | 1 096 | 1 580 |
EBITDA margin
-7744100.0%
This company
15.8%
Market median
-49013391% vs market
20202024
Equity ratio
74.4%
This company
38.2%
Market median
+95% vs market
20202024
Return on equity
-1.7%
This company
18.4%
Market median
-109% vs market
20202024
Net profit margin
-7663700.0%
This company
8.1%
Market median
-94613680% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.34×
This company
0.62×
Market median
+45% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JL Chief Auditor | Chief Auditor | 2022 |
MH Chief Executive Officer | Chief Executive Officer | 2020 |
| Former (1) | ||
LA | Audit | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Lisubron AB 
Rama Medical AktiebolagBoard members of Lisubron AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Josef Lasse Bergerheim | Chief Auditor | 0 companies |
| Liisa Anne Kristiina Potila | Audit | 0 companies |
| Maria Helena Stjernberg Åkermark | Chief Executive Officer | 0 companies |
| Henrik Wilhelm Åkermark | Deputy Board Member | 0 companies |